醛糖还原酶在非糖尿病疾病中作用的最新研究进展

摘要/Abstract

摘要： 醛糖还原酶属于醛酮还原酶超家族中重要的一员,是糖代谢途径中多元醇通路的限速酶。醛糖还原酶通过调节细胞因子、生长因子、氧化应激等介导的细胞内信号转导通路,参与多种疾病病理过程。本文主要综述了醛糖还原酶在非糖尿病疾病中的最新研究进展。

关键词: 醛糖还原酶, 糖尿病, 非糖尿病疾病

Abstract: Aldose reductase belongs to aldo-keto reductase superfamily, which catalyzes the rate limiting step of the polyol pathwany. To date, emerging reports have suggested that aldose reductase mediates intracellular signal transduction pathways that triggered by cytokines, growth factors and oxidative stress. Then aldose reductase is involved in various of pathological processes of diseases. This paper summarized the role of aldose reductase in the non-diabetic diseases.

Key words: Aldose reductase, Diabetes mellitus, Non-diabetic disease

中图分类号:

R977.3

邓晓兰, 李慧, 景贤, 田莹莹, 吕佩瑜, 欧阳冬生. 醛糖还原酶在非糖尿病疾病中作用的最新研究进展[J]. 中国临床药理学与治疗学, 2011, 16(5): 590-594.

DENG Xiao-lan, LI Hui, JING Xian, TIAN Ying-ying, LV Pei-yu, OUYANG Dong-sheng. Recent progress of aldose reductase in non-diabetic disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 590-594.

参考文献

[1] 谷娟, 严谨, 吴卫华, 等. 醛糖还原酶的研究进展[J]. 中南大学学报:医学版,2010,35(4): 395-400.
[2] 王俊杰, 康桢, 李茯酶, 等. 醛糖还原酶:心肌缺血损伤干预的新靶点[J]. 国际病理科学与临床杂志, 2007, 27 ( 3 ) : 211-213.
[3] Anil Kumar P, Bhanuprakash Reddy G. Focus on molecules: aldose reductase[J]. Exp Eye Res, 2007,85(6):739-740.
[4] Fournier B, Bendeifel E, Guillot B, et al. Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase[J]. J Am Chem Soc, 2009, 131(31):10929-10941.
[5] Ramana KV, Srivastava SK. Aldose reductase: A novel therapeutic target for inflammatory pathologies[J]. Int J Biochem Cell Biol, 2010, 42(1):17-20.
[6] 欧阳冬生, 黄琪, 刘黎, 等. 醛糖还原酶在糖尿病并发症和心血管病变中的作用[J]. 中国现代医学杂志, 2008, 18(17):2506-2509.
[7] Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy[J]. Int Ophthalmol Clin, 2009, 49(2):35-52.
[8] Wu JC, Li XH, Wang JB, et al. Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes[J]. Genet Test Mol Biomarkers, 2011, 15(4):273-279.
[9] Uthra S, Raman R, Mukesh BN, et al. Diatetic retinopathy: validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south indian cohort[J]. Ophthalmic Genet, 2010, 31(4):244-251.
[10] Abhery S, Burdon KP, Laurie KJ, et al. Aldose reductase gene polymorphisms and diabetic retinopathy suscepibility[J]. Diabetes Care, 2010, 33 (8):1834-1836.
[11] Prasad P, Tiwari AK, Kumar KM, et al. Association analysis of ADPRT1, AKR1B1, RAGE, GFT2 and PAI-1 gene polymorphisms with chronic renal insufficency among Asian Indians with tpype-2 diabetes[J]. BMC Med Genet, 2010, 11:52.
[12] Kariserova K, Srivastava S, Hoetker JD. Redox activation of aldose reductase in the ischemic heart[J]. J Biol Chem, 2006, 281(22):15102-15120.
[13] Kaiserova K, Tang XL, Srivastava S, et al. Role of nitric oxide in regulating aldose reductase activation in the ischemic heart[J]. J Biol Chem, 2008, 283(14):9101-9112.
[14] Hwang YC, Kaneko M, Bakr S, et al. Central role for aldose reductase pathway in myocardial ischemic injury[J]. FASEB J, 2004, 18(11):1192-1199.
[15] Hwang YC, Shaw S, Kaneko M, et al. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury[J]. FASEB J, 2005, 19(7):795-797.
[16] Ananthakrishnan R, Kaneko M, Hwang YC, et al. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore[J]. Am J Physiol Heart Circ Physiol, 2009, 296(2):H333-341.
[17] Iwaka K, Matsuno K, Nishinaka T, et al. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism[J]. J Pharmacol Sci, 2006, 102:37-46.
[18] Keith RJ, Haberzettl P, Vladykovskaya E, et al. Aldose reductase decreases endoplasmic reticulum stress in ischemic hearts[J]. Chem Biol Interact, 2009, 178(1/2/3 ) : 242-249.
[19] Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis[J]. Acta Med Indones, 2007, 39(2) : 86-93.
[20] Tammali R, Saxena A, Srivastava SK, et al. Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle[J]. Endocrinology, 2010, 151(5) : 2140-2150.
[21] Liu X, Shen J, Zhan R, et al. Propeomic analysis of homocysteine induced proliferation of cultured neonatal rat vascular smooth muscle cells[J]. Biochim Biophys Acta, 2009, 1794(2) : 177-184.
[22] Gu J, Wang JJ, Yan J, et al. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling[J]. J Ethnopharmacol, 2010, 133(1) : 6-13.
[23] Srivastava S, Vladykovskaya E, Barski OA, et al. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice[J]. Cir Res, 2009, 105(8): 793-802.
[24] Ramana KV, Bhantnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-a-induced expression of adhesion molecules in endothelial cells[J]. FASEB J, 2004, 18(11): 1209-1218.
[25] Ramana KV, Fadl AA, Tammali R, et al. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages[J]. J Biol Chem, 2006, 281(44): 33019-33029.
[26] Ramana KV, Reddy AB, Tammali R, et al. Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages[J]. Free RadIC Biol Med, 2007, 42(8): 1290-1302.
[27] Ramana KV, Willis MS, White MD, et al. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition[J]. Circulation, 2006, 114(17): 1838-1846.
[28] Reddy AB, Srivastava SK, Ramana KV. Aldose reductase inhibition prevents lipopolysaccharide-induced glucose uptake and glucose transporter 3 expression in RAW264.7 macrophages[J]. Int J Biochem Cell Biol,2010, 42 ( 6 ) : 1039-1045.
[29] Yadav UC, Ramana KV, Aguilera-Aguirre L, et al. Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice[J]. PLoS One, 2009, 4 ( 8 ) : e6535.
[30] Ravindranath TM, Mong PY, Ananthakrishnan R, et al. Novel role for aldose reductase in mediating acute inflammatory responses in the lung[J]. J Immunol, 2009, 183 (12) : 8128-8137.
[31] Yadav UC, Srivastava SK, Ramana KV. Understanding the role of aldose reductase in ocular inflammation[J]. Curr Mol Med, 2010, 10(6) : 540-549.
[32] Wang C, Yan R, Luo D, et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls[J]. J Biol Chem, 2009, 284(39) : 26742-26748.
[33] Tammali R, Ramana KV, Singhal SS, et al. Aldose reductase regulates growth factor-induced cyclooxy-genase-2 expression and prostaglandin E₂ production in human colon cancer cells[J ] . Cancer Res, 2006, 66(19) : 9705-9713.
[34] Ramana KV, Tammali R, Srivastava SK. Inhibition of aldose reductase prevents growth factor-induced G₁-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells[J ] . Mol Cancer Ther, 2010, 9(4):813-824.
[35] Tammali R, Reddy AB, Ramana KV, et al. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation[J]. Carcinogenesis, 2009, 30(5) : 799-807.
[36] Lefranois-Martinez AM, Bertherat J, Val P, et al. Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors[J]. J Clin Endocrinol Metab, 2004, 89 ( 6 ) : 3010-3019.
[37] Plebuch M, Soldana M, Hungerera C, et al. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes[J]. Cancer Lett, 2007, 255 : 49-56.
[38] 何晓峰, 赵晓琴, 刘晓城, 等. 黄芪对左肾静脉狭窄大鼠肾组织病理学与转化生长因子-β₁表达的影响[J ] . 医药导报, 2008, 27(5) : 509-510.
[39] Zhang Y, Huang P, Jiang T, et al. Role of aldose reductase in TGF-beta1-induced fibronectin synthesis in human mesangial cells [ J ] . Mol Biol Rep, 2010, 37 ( 6 ) : 2735-2742.
[40] Huang P, Zhang Y, Jiang T, et al. Aldose reductase is a potent regulator of TGF-β1 induced expression of fibronectin in human mesangial cells[J]. Mol Biol Rep, 2010, 37(7) : 3097-3103.
[41] Hasuike Y, Moriguchi R, Hata R, et al. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis[J]. Am J Nephrol, 2007, 27(6) : 622-629.
[42] Lo ACY, Cheung A, Hung VKL, et al. Deletion of aldose reductase leads to protection against cerebral ischemic injury[J]. J Cereb Blood Flow Metab, 2007, 27(8) : 1496-1509.
[43] Yagihashi S, Mizukami H, Ogasawara S, et al. The role of the poyol pathway in acute kidney injury caused by hindlimb ischaemia in mice[J]. J pathol, 2010, 220(5) : 530-541.
[44] Obrosova IG, Maksimchyk Y, Pacher P, et al. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina[J]. Int J Mol Med, 2010, 26(1) : 135-142.
[45] Hallam KM, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats[J]. Aging Cell, 2010, 9(5) : 776-784.
[46] Kabututu Z, Manin M, Pointu JC, et al. Prostaglandin F 2a sythase avtivities of aldos-keto reductase 1B1,1B3 and 1B7[J]. J Biochemistry, 2009, 145(2) : 161-168.
[47] Bresson E, Boucher-Kovalik S, Chapdelaine P, et al.The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium[J]. J Clin Endocrinol Metab, 2011, 96(1): 210-219.